These findings suggest that PCSK9 regulate inflammation in lung and thus PCSK9 inhibition may be beneficial in reducing inflammation and improving outcomes in severe COVID-19 cases, especially in patients with high levels of inflammation. This evidence concerns the gene PCSK9 and COVID-19.